TCM
DRNA

Tuttle Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Tuttle Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,903
Closed -$258K – 294
2021
Q2 		$258K Buy
+6,903
New +$212K 0.11% 218

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Tuttle Capital Management's DRNA Position: Q3 2021 in Review

Tuttle Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 6,903 shares — an estimated $258K sold.

Tuttle Capital Management first reported a position in DRNA in Q2 2021 and held it in 1 quarter. The position peaked at $258K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

  • Tuttle Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Tuttle Capital Management sold 6,903 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $258K.
  • Tuttle Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2021 and held it in 1 quarter.
  • Tuttle Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $258K in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Tuttle Capital Management's 13F filing for Q3 2021, filed 20 Oct 2021.